MRNS vs. KRON, EQ, LABP, LTRN, CELU, IMMX, RLYB, CARM, EGRX, and HCWB
Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include Kronos Bio (KRON), Equillium (EQ), Landos Biopharma (LABP), Lantern Pharma (LTRN), Celularity (CELU), Immix Biopharma (IMMX), Rallybio (RLYB), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
Kronos Bio (NASDAQ:KRON) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
Kronos Bio has higher earnings, but lower revenue than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Marinus Pharmaceuticals has a net margin of -456.31% compared to Marinus Pharmaceuticals' net margin of -1,791.87%. Marinus Pharmaceuticals' return on equity of -58.79% beat Kronos Bio's return on equity.
Kronos Bio presently has a consensus price target of $4.25, indicating a potential upside of 342.71%. Marinus Pharmaceuticals has a consensus price target of $16.07, indicating a potential upside of 989.59%. Given Kronos Bio's higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Kronos Bio.
Marinus Pharmaceuticals received 408 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 69.22% of users gave Marinus Pharmaceuticals an outperform vote while only 65.38% of users gave Kronos Bio an outperform vote.
64.1% of Kronos Bio shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 23.4% of Kronos Bio shares are held by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Marinus Pharmaceuticals had 16 more articles in the media than Kronos Bio. MarketBeat recorded 16 mentions for Marinus Pharmaceuticals and 0 mentions for Kronos Bio. Marinus Pharmaceuticals' average media sentiment score of 0.00 beat Kronos Bio's score of -0.12 indicating that Kronos Bio is being referred to more favorably in the media.
Kronos Bio has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Summary
Kronos Bio beats Marinus Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Marinus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marinus Pharmaceuticals Competitors List
Related Companies and Tools
